We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 185

Patent misuse in the pharmaceutical industry: developments in US & EU
  • Gowling WLG
  • European Union, USA
  • October 31 2007

The pharmaceutical industry has been scrutinised closely by competition authorities and courts in the US and Europe


Generics v Lundbeck - distinguishing the sufficiency requirements for product and process claims
  • Gowling WLG
  • United Kingdom
  • May 19 2008

In Generics v Lundbeck, the Court of Appeal provided important guidance on the judgment of the House of Lords in Biogen v Medeva regarding the scope of protection to which an inventor is entitled and the enabling disclosure the specification must provide to support the claims in the patent


Apotex v. Adir
  • Gowling WLG
  • Canada
  • July 27 2009

The Court of Appeal upheld the decision of the Trial Division finding that the patent was both valid and infringed


Implemention of “Bolar” in the EU
  • Gowling WLG
  • European Union, United Kingdom
  • October 31 2007

In Europe, Directive 200427EC (amending Directive 200183EC) introduced into European Union legislation for the first time an exemption from patent infringement for conducting certain developmental work pre-patent expiry (the EU ‘Bolar’ exemption


Pfizer v. Novopharm
  • Gowling WLG
  • Canada
  • June 24 2009

The Federal Court granted prohibition in respect of a patent claiming the use of sildenafil for the treatment of erectile dysfunction by oral administration


Apotex v. Canada (Minister of Health)
  • Gowling WLG
  • Canada
  • May 28 2009

Apotex brought a judicial review of the Minister’s refusal to issue a NOC regarding its version of aspirin


Sanofi v ratiopharm, PMNOC Regulations decision irbesartan, March 5, 2010
  • Gowling WLG
  • Canada
  • May 21 2010

Sanofi sought an order prohibiting the granting of a NOC to ratiopharm


Arrow hits a bullseye against Merck’s divisional patent applications
  • Gowling WLG
  • United Kingdom
  • August 20 2007

This is a dispute between Arrow Generics Limited (“Arrow”) and Merck & Co. Inc (“Merck”


Apotex v Servier; appeal of interlocutory motion; November 1, 2007 - perindopril
  • Gowling WLG
  • Canada
  • November 16 2007

The Federal Court of Appeal overturned the decision of the Federal Court and reinstated a number of paragraphs in the Statement of Defence and Counterclaim relating to the issue of inventorship


Pfizer v Ranbaxy; 55.2 proceeding; October 5, 2007 - atorvastatin
  • Gowling WLG
  • Canada
  • October 25 2007

The trial judge granted prohibition in respect of one patent claiming a novel crystalline form of atorvastatin (the "crystalline form patent") and denied prohibition in respect of another patent claiming a novel process for making atorvastatin (the "process patent"